Phoenix Life Announces Annual Financial Report Filings for 2017 and 2018
DENVER, CO – April 26, 2019 – Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”, the “Company”), an international adaptive healthcare solutions company, today announced that it has completed filing its Form 10-Quarterly Reports and Form 10-K Annual Reports, including audited financial reports, with the Securities and Exchange Commission (”SEC”) for the 2017 and 2018 fiscal years as part of the Company’s 2018 merger and consolidation.
Phoenix Life was created through a consolidation of multiple domestic and international businesses. The filing of these 2017 and 2018 reports, and subsequent quarterly reports will bring the Company current with its reporting requirements with the SEC. Phoenix Life intends to remain a fully reporting public company to provide full transparency with the SEC and investing public.
Following OTC Markets update of reporting status to Current, Phoenix Life intends to begin the process of uplisting onto the OTCQB market, in parallel with launching a capital offering to fund the next stages of development and execution for the Company.
“The Phoenix Life team has been working diligently to bring the reports of the Company current including all reports pre and post-merger. Complete transparency in all aspects of our business remains a high priority,” said Martin Tindall, CEO and Founder of Phoenix Life. “As Phoenix Life moves forward with the legal global distribution of its medical cannabis derived pharmaceutical products and programs for managing healthcare, our underlying corporate compliance is a key priority for the Company.”
In March 2019, Phoenix Life announced the filing its 2015 and 2016 Form 10-K Annual Reports.
The Company is currently performing widespread diabetes screenings across the Republic of Vanuatu in advance of launching clinical trials on the efficacy of its diabetes treatment in conjunctuion with leading Australian Universities and Ethics Committees.
To learn more about Phoenix Life Sciences International, please visit http://phoenixlife.co/.
About Phoenix Life Sciences International Limited
Phoenix Life Sciences International Limited is an adaptive healthcare solutions company. Our business is to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders. We strive to create partnerships and integrate these programs for human health into communities worldwide as part of our Global Health Initiative.
Information contained in this press release regarding Phoenix Life Sciences International, Limited and its subsidiaries, (the “Companies”) may constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Companies herein are expressly qualified in their entirety by the above-mentioned cautionary statement. The Companies disclaim any obligation to update forward-looking statements contained in this press release, except as may be required by law.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and therefore the products sold by Phoenix Life Sciences International are not available in the U.S.
Phoenix Life Sciences International does not sell or distribute any products in the United States that are in violation of the United States Controlled Substances Act (US.CSA). This company does not grow, sell, and distribute cannabis-based products in the United States and is solely involved with the legal distribution of medical cannabis-based products within certain international markets outside of the United States.
Phone: 1.888.717.5655 or international +1.720.699.7222